Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Polycystic Kidney, Autosomal Dominant: early-phase trial registry
A small indexed set (5 trials) with no open enrollment listed right now.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · none currently recruiting · #3,391 of 28,707 conditions by registered trial count
Polycystic Kidney, Autosomal Dominant: 5 US clinical trials tracked, none currently recruiting.
Polycystic Kidney, Autosomal Dominant is the subject of 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 3 of these trials.
Enrollment posture brief
Registry condition polycystic-kidney-autosomal-dominant
OPEN 0 | RECR 0% | LATE 1 | EARLY 3 | RANK #3391 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Polycystic Kidney, Autosomal Dominant has no open enrollment in this registry pull (5 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Polycystic Kidney, Autosomal Dominant on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Polycystic Kidney, Autosomal Dominant is recruiting below its size-band peers.
0 of 5 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Polycystic Kidney, Autosomal Dominant research.
University of Colorado, Denver accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Polycystic Kidney, Autosomal Dominant trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Polycystic Kidney, Autosomal Dominant research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
University of Colorado, Denver
NCT05510115
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
University of Colorado, Denver
NCT00456365
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
Kyongtae Ty Bae, M.D., Ph.D.
NCT02656017
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
University of Colorado, Denver
NCT03342742
Effect of Venglustat in Patients With Renal Impairment
Genzyme, a Sanofi Company
NCT03687554
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Polycystic Kidney, Autosomal Dominant records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Polycystic Kidney, Autosomal Dominant trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Polycystic Kidney, Autosomal Dominant page
5 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Polycystic Kidney, Autosomal Dominant trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- University of Colorado, Denver sponsors the most Polycystic Kidney, Autosomal Dominant trials on record, review their full trial history before evaluating a specific study. See University of Colorado, Denver's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Polycystic Kidney, Autosomal Dominant condition card totals 5 registered trials; most-linked intervention Placebo; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.